Bestivan extends time to quality adjustment in advanced renal cell carcinoma without symptoms or toxicity

Although the time to grade 3/4 toxicity before disease progression (TOX) was numerically longer for Belzutifan vs. Everolimus in patients with advanced renal cell carcinoma (RCC), the fundamental According to quality-adjusted time-without symptoms or toxicity (Q-TWiST) analysis of the LITESPRAK-005 Phase 3 trial (NCT04195750), Bestivan produced clinically meaningful and statistically significant improvements in quality-adjusted survival time.

Results from the primary analysis published in 2025 showed that the mean Q-TWiST was 17.47 months for patients who received bezotivan (n=374) and 14.81 months for patients who received everolimus (n=372; difference, 2.66; 95% CI, 1.06-4.49). In the primary analysis, the Q-TWiST relative gain for bezotivan was 11.32% (range 4.49%-19.09%), defined as the absolute Q-TWiST difference divided by mean overall survival (OS) in the everolimus group.

Sensitivity analyzes including grade 1 to 4 serious adverse events showed that the mean Q-TWiST was 17.50 months in the bezotivan group and 15.03 months in the everolimus group (difference 2.47; 95% CI 0.81-4.28). The data shows that in sensitivity analysis, the relative gain of Q-TWiST is 10.50% (range 3.44%-18.18%).

In summary, from a response and progression-free survival [PFS] perspective, bezotivan performed better than everolimus. The toxicity profile was clear and the quality of life was better, as were the TWiST and Q-TWiST analyses. This kind of[Q-TWiST analysis] really helps patients and doctors make decisions.

As part of this analysis, investigators divided patient survival time after randomization into 3 mutually exclusive categories: time to investigator-assessed disease progression to grade 3/4 adverse effects (AEs), time to progression to symptom-free and grade 3/4 toxicity (TWiST), and time from progression to death (REL). In addition, standard utility weights used in the literature - 1 for TWiST and 0.5 for TOX and REL - were considered and a threshold utility analysis was performed to determine the impact of different health state utilities.

The study authors summarized treatment effects as the difference in finite mean time spent in each state;The difference in Q-TWiST; and the relative gain in Q-TWiST or the absolute Q-TWiST difference divided by mean OS in the everolimus group. Non-parametric bootstrapping methods were used to generate 95% confidence intervals for treatment differences related to health status and Q-TWiST.

In the multicenter, open-label Phase 3 LITESPARK-005 trial, patients were randomized 1:1 to receive 120 mg of bestivan or everolimus 10 mg orally once daily until disease progression or unacceptable toxicity. The trial's dual primary endpoints were PFS based on blinded independent central review (BICR) according to RECIST v1.1 criteria and OS. Secondary endpoints include objective response rate, duration of response and safety according to RECIST v1.1 guidelines.

Patients 18 years and older with stage IV clear cell renal cell carcinoma, a Karnofsky performance status of 70 or greater, at least 1 measurable lesion according to RECIST v1.1 guidelines, and disease progression following prior therapy with a PD-(L)1 inhibitor and a VEGFR tyrosine kinase inhibitor are eligible to participate in the trial. Three or fewer lines of systemic treatment are required for study entry.

In the primary analysis, the mean time to TOX was 1.45 months in the bezotivan group and 1.22 months in the everolimus group (difference, 0.23; 95% CI, -0.29 to 0.76). Although numerically, patients in the bezotivan group had longer TOX times, the data show that bezotivan treatment< The time to span>TWiST was significantly longer, with a mean of 10.73 months compared with 6.07 months with everolimus, which was driven by the long-term absence of progression (difference, 4.66 months; 95% CI, 3.28-6.02).

Previous safety data showed that the most common adverse events of any grade in the bezotivan group and everolimus group included anemia (83.1% vs. 57.1% in the everolimus group, respectively). 2%), fatigue (32.3% vs. 25.8%), nausea (18.5% vs. 12.2%), peripheral edema (17.2% vs. 18.1%), and constipation (16.9% vs. 8.3%).

Reference materials:https://www.onclive.com/view/belzutifan-prolongs-quality-adjusted-time-without-symptoms-or-toxicity-in-advanced-rcc